Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer.

Yan-Song LinXin ZhangChen WangYan-Qing LiuWen-Min GuanJun Liang

Published in: The Journal of clinical endocrinology and metabolism (2021)

In this long-term evaluation, apatinib displayed sustainable efficacy and tolerable safety profile, warranting it as a promising treatment option for progressive RAIR-DTC.

Keyphrases

multiple sclerosis
open label
clinical trial
study protocol
replacement therapy
placebo controlled
double blind